Correction to "The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes".
出版信息
Diabetes Obes Metab. 2025 May;27(5):2906. doi: 10.1111/dom.16323. Epub 2025 Mar 13.
Abstract
摘要
相似文献
1
Correction to "The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes".
Diabetes Obes Metab. 2025 May;27(5):2906. doi: 10.1111/dom.16323. Epub 2025 Mar 13.
2
The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.糖化血红蛋白（HbA1c）变异性对2型糖尿病患者强化血压控制疗效的影响。
Diabetes Obes Metab. 2025 Mar;27(3):1208-1216. doi: 10.1111/dom.16112. Epub 2024 Dec 3.
3
Effects of intensive glycemic control on microvascular outcomes in type 2 diabetes mellitus are modified by long-term HbA variability: A post hoc analysis of the ACCORD trial.强化血糖控制对 2 型糖尿病患者微血管结局的影响受长期 HbA 变异性的影响：ACCORD 试验的事后分析。
Diabetes Res Clin Pract. 2024 Feb;208:111100. doi: 10.1016/j.diabres.2024.111100. Epub 2024 Jan 20.
4
Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in individuals with type 1 diabetes: An observational study.糖化血红蛋白变异性和收缩压变异性与 1 型糖尿病患者的死亡率显著相关且具有相加作用：一项观察性研究。
Diabetes Obes Metab. 2018 Apr;20(4):1014-1017. doi: 10.1111/dom.13193. Epub 2018 Jan 18.
5
Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.用于 1 型和 2 型成年糖尿病患者群体的持续皮下胰岛素输注（CSII）泵：一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(20):1-58. Epub 2009 Oct 1.
6
Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes.速效胰岛素类似物与常规人胰岛素对比：糖尿病患者血糖控制效果的荟萃分析
Diabetes Ther. 2020 Mar;11(3):573-584. doi: 10.1007/s13300-019-00732-w. Epub 2019 Dec 23.
7
Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study.血糖控制、HbA1c 变异性与心血管风险升高的 2 型糖尿病患者的主要心血管不良结局：来自 ACCORD 研究的见解。
Cardiovasc Diabetol. 2023 Oct 27;22(1):287. doi: 10.1186/s12933-023-02026-9.
8
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.强化多因素干预对 2 型糖尿病患者心血管结局和死亡的影响（J-DOIT3）：一项开放标签、随机对照试验。
Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24.
9
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.联合强化血压和血糖控制并不能为 2 型糖尿病患者的微血管结局带来额外获益。
Kidney Int. 2012 Mar;81(6):586-94. doi: 10.1038/ki.2011.415. Epub 2011 Dec 14.
10
Risk factor variability and cardiovascular risk among patients with diabetes: a nationwide observational study.糖尿病患者的风险因素变异性与心血管风险：一项全国性观察研究。
Eur J Prev Cardiol. 2023 Jun 1;30(8):719-727. doi: 10.1093/eurjpc/zwad072.
本文引用的文献
1
The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.糖化血红蛋白（HbA1c）变异性对2型糖尿病患者强化血压控制疗效的影响。
Diabetes Obes Metab. 2025 Mar;27(3):1208-1216. doi: 10.1111/dom.16112. Epub 2024 Dec 3.
Zotero 插件